171504-98-6

Basic information

• Product Name: 1,4-DI-TERT-BUTYL 2-METHYL PIPERAZINE-1,2,4-TRICARBOXYLATE
• Synonyms: 1,4-DI-TERT-BUTYL 2-METHYL PIPERAZINE-1,2,4-TRICARBOXYLATE;1,4-di-Boc-piperazine-2-carboxylic acid Methyl ester;1,2,4-Piperazinetricarboxylic acid, 1,4-bis(1,1-diMethylethy;Methyl 1,4-Bis(Boc)-2-piperazinecarboxylate;1,4-bis(tert-butoxycarbonyl)-2-methylpiperazine-2-carboxylic acid;1,2,4-Piperazinetricarboxylic acid, 1,4-bis(1,1-dimethylethyl) 2-methyl ester;1-O,4-O-ditert-butyl 2-O-methyl piperazine-1,2,4-tricarboxylate
• CAS NO: 171504-98-6
• Molecular Formula: C₁₆H₂₈N₂O₆
• Molecular Weight: 344.40332
• Mol File: 171504-98-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 406.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.145±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -0.27±0.70(Predicted)
• CAS DataBase Reference: 1,4-DI-TERT-BUTYL 2-METHYL PIPERAZINE-1,2,4-TRICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DI-TERT-BUTYL 2-METHYL PIPERAZINE-1,2,4-TRICARBOXYLATE(171504-98-6)
• EPA Substance Registry System: 1,4-DI-TERT-BUTYL 2-METHYL PIPERAZINE-1,2,4-TRICARBOXYLATE(171504-98-6)

Safety Data

• Hazardous Substances Data: 171504-98-6(Hazardous Substances Data)

Usage

Description

1,4-Di-tert-butyl 2-methyl piperazine-1,2,4-tricarboxylate is an organic compound characterized by its unique molecular structure, featuring a piperazine core with tert-butyl and methyl groups as well as three carboxylate groups. 1,4-Di-tert-butyl 2-methyl piperazine-1,2,4-tricarboxylate is known for its potential applications in various chemical and pharmaceutical processes due to its versatile reactivity and structural properties.

Uses

Used in Asymmetric Hydrogenation:
1,4-Di-tert-butyl 2-methyl piperazine-1,2,4-tricarboxylate is used as a reagent in the asymmetric hydrogenation of tetrahydropyrazines. Its unique structure allows for selective hydrogenation, leading to the formation of chiral products with high enantioselectivity and yield. This application is particularly relevant in the synthesis of complex organic molecules and pharmaceutical compounds, where the control of stereochemistry is crucial for biological activity and efficacy.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 2758-98-7 2-methoxycarbonyltetrahydropyrazine 
• 144-55-8 sodium hydrogencarbonate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 181955-79-3 N,N'-di-tert-butyloxycarbonylpiperazine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 129799-08-2 tert-butyl methyl piperazine-1,3-dicarboxylate 
• 2762-32-5 piperazine-2-carboxylic acid 
• 85622-93-1 temozolomide 

Downstream Products

• 181955-79-3 N,N'-di-tert-butyloxycarbonylpiperazine-2-carboxylic acid 
• 122323-88-0 piperazine-2-carboxylic acid methyl ester dihydrochloride 
• 143540-05-0 2-hydroxymethylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 2758-98-7 2-methoxycarbonyltetrahydropyrazine 
• 1092478-40-4 (+/-)-bis(1,1-dimethylethyl) 2-[3-(ethyloxy)-3-oxopropyl]-2-methyl-1,4-piperazinedicarboxylate 
• 129799-11-7 1-benzyl 3-methyl piperazine-1,3-dicarboxylate 

Relevant articles and documents

BRM TARGETING COMPOUNDS AND METHODS OF USE THEREOF

The present invention relates to bifunctional compounds comprising a binding fraction to a target protein and a binding fraction to ubiquitin ligase E3, and associated methods of use.

Piperazine compound and application thereof in preparation of chemokine receptor CCR2 antagonist

The invention relates to a piperazine compound as shown in a formula (I) and an application of the piperazine compound in preparation of a chemokine receptor CCR2 antagonist or a medicine for treatingCCR2-mediated diseases.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.